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Abstract Micafungin is an echinocandin with potent
activity against a broad range of fungal species, including
Candida species. The pharmacokinetic and safety profiles
of micafungin have been evaluated in individuals with
mild-to-moderate hepatic dysfunction, but not in individ-
uals with severe hepatic dysfunction. Therefore, the present
study assessed the pharmacokinetics and safety of a single
100 mg dose of micafungin in healthy subjects (n = 8) and
subjects with severe hepatic dysfunction (n = 8). Mean
maximum plasma concentration of micafungin and mean
area under the plasma micafungin concentration–time
curve extrapolated to infinity were lower in subjects
with severe hepatic dysfunction (7.3 ± 2.4 lg/mL and
100.1 ± 34.5 hlg/mL, respectively) than in subjects
with normal hepatic function (10.3 ± 2.5 lg/mL and
142.4 ± 28.9 hlg/mL, respectively). Mean clearance
was higher in subjects with severe hepatic dysfunction
(1,098 ± 347 mL/h) than in subjects with normal hepatic
function (728 ± 149 mL/h). Concentrations of albumin in
subjects with severe hepatic dysfunction were lower.
Assessments of micafungin plasma protein binding sug-
gested that the higher clearance in subjects with severe
hepatic dysfunction may be due to higher unbound con-
centrations. However, the magnitude of the differences was
not considered clinically meaningful and is comparable
with exposures reported elsewhere for a 100-mg dose in
patients treated for invasive candidiasis. Thus, dose
adjustment in subjects with severe hepatic dysfunction is
not warranted. Micafungin was well tolerated in all sub-
jects throughout the study.
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1 Introduction
Candidaemia and invasive candidiasis are the most com-
mon invasive fungal infections, and the incidence of these
serious diseases is rising (Pfaller and Diekema 2007). In
Europe, Candida albicans is responsible for [50 % of
cases of invasive candidaemia; however, non-albicans-
related Candida infections are also increasing (Lass-Flo¨rl
2009).
Micafungin is an injectable echinocandin antifungal
agent that displays potent activity against a broad range of
Candida species (Jarvis et al. 2004; Messer et al. 2006). It
has demonstrated efficacy similar to that of liposomal
amphotericin B and caspofungin for the treatment of
invasive candidiasis and candidaemia (Kuse et al. 2007;
Pappas et al. 2007) and to that of fluconazole for the
treatment of oesophageal candidiasis (de Wet et al. 2005).
Moreover, it exhibits superior efficacy and comparable
safety to fluconazole for the prophylaxis of invasive fungal
infections in patients undergoing haematopoietic stem cell
transplantation (van Burik et al. 2004).
Micafungin is metabolised in the liver and is mainly
excreted in bile (Fromtling 2002); it undergoes metabolism
to three metabolites: M-1, formed by metabolism of the
parent drug; M-2, formed by degradation of M-1; and M-5,
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formed by hydroxylation of the side chain of micafungin
by CYP450 enzymes. However, metabolism by the
CYP450 system plays only a minor role in the degradation
of micafungin (Wiederhold and Lewis 2007).
Previous pharmacokinetic (PK) studies of micafungin
have been conducted in healthy adults (Hebert et al. 2005a,
b, c; Keirns et al. 2007), HIV-positive adults with con-
firmed oesophageal candidiasis (Undre et al. 2012a), adults
and children with invasive candidiasis and candidaemia
(Undre et al. 2012b, c), neonates with suspected candida-
emia or invasive candidiasis (Benjamin et al. 2010) and
subjects with mild-to-moderate hepatic dysfunction (He-
bert et al. 2005b). The recommended daily dose for the
treatment of adults with invasive candidiasis and candida-
emia is 100 mg. This results in the following mean steady-
state PK parameters: area under the plasma concentration–
time curve over dosage time interval 0–24 h (AUC0–24),
97 hlg/mL; maximum plasma concentration (Cmax),
10.5 lg/mL; clearance (CL), 1,168 mL/h and half-life (t),
14–15 h (Undre et al. 2012b).
In a study in subjects with moderate hepatic dysfunction
(Child–Pugh score 7–9), AUC extrapolated to infinity
(AUC?) and Cmax of micafungin were lower, and CL
higher, compared with healthy subjects, but the differences
were not considered to be clinically relevant (Hebert et al.
2005b). Exposure was comparable with that observed for a
100-mg dose in patients treated for invasive candidiasis
(Undre et al. 2012b). Thus, dose adjustment was not con-
sidered necessary in subjects with mild-to-moderate hepa-
tic dysfunction. However, there are no data on the PK and
safety of micafungin in individuals with severe hepatic
dysfunction. Therefore, this study was designed to char-
acterise the PK and safety profiles of micafungin following
administration of a single dose of 100 mg to individuals
with severe hepatic dysfunction.
2 Methods
2.1 Subjects and study design
This was a single-dose, open-label study in which subjects
with severe hepatic dysfunction (Child–Pugh score 10–12)
and healthy, control subjects were enrolled and matched
1:1 for age (within 10 years), weight (within 20 %), sex
and race. All subjects were aged between 18 and 75 years
and within 35 % of their ideal body weight. Subjects were
excluded from the study if they had received any pre-
scribed systemic or topical medication within 14 days of
receiving study drug, non-prescribed systemic or topical
medication within 7 days (except vitamin or mineral
supplements or paracetamol or contraceptives in healthy
females) or any medications known to chronically alter
drug absorption or elimination within 30 days. Subjects
were also excluded if they had participated in a clinical
study of a drug within the previous month, had a known
history of lactose or gluten intolerance, clinically signifi-
cant allergic disease, other significant illness within
3 months of the start of the study, multiple drug allergies
or allergy to the micafungin drug class, supine blood
pressure and supine pulse rate at screening higher than
150/100 mmHg and 100 beats per min, respectively, or
lower than 100/50 mmHg and 40 beats per min, respec-
tively, positive drug screen, pregnancy test or test for HIV
antibodies or clinically relevant coagulation abnormalities.
In addition, any subjects with medical history or clinical
or laboratory findings indicative of acute or chronic dis-
ease that, in the opinion of the investigator, might influ-
ence study outcome, a history of any clinically significant
neurological, gastrointestinal, renal, hepatic, cardiovascu-
lar, psychiatric, respiratory, metabolic, endocrine, haema-
tological or other major disorder (normal hepatic
function), or an invasive infection that required treatment
(severe hepatic dysfunction) were also excluded from the
study.
Eligibility was assessed by physical examination, vital
signs, 12-lead electrocardiogram, drug and alcohol screen,
clinical laboratory parameters and medical history con-
ducted B15 days before administration of study drug (Day
1) with confirmation of eligibility criteria on Day 1. On
Day-1, all subjects received a single dose of micafungin
100 mg. All eligible subjects were hospitalised for the
study period (Day-1 to Day 5).
Written, informed consent approved by the local inde-
pendent ethics committee, the Ethics Committee of the
Faculty of Health Sciences of the University of the Free
State and the South African Medicines Control Council
was obtained from all participants prior to all study pro-
cedures. The study was conducted in accordance with the
principles set forth in the Declaration of Helsinki as
amended in Tokyo, 2004, and the Guidelines of the Inter-
national Conference on Harmonization on Good Clinical
Practice.
2.2 Chemicals and drugs
Micafungin was supplied in vials containing lyophilised
micafungin powder 50 mg plus lactose 200 mg, together
with 0.9 % sodium chloride solution for injection in
250 mL infusion bags.
2.3 Drug administration
On Day 1 each subject received a single infusion of mi-
cafungin 100 mg at a constant rate of 100 mL/h for 1 h,
administered intravenously via a cannula. Each subject
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received a total of 100 mL of intravenous dosing solution.
Subjects remained supine during the entire infusion period.
2.4 Blood sampling and assays
Blood samples (10 mL) were collected by venous punc-
ture or indwelling cannula of a forearm vein or veins
(opposite arm to that receiving the infusion) into sodium
heparinized tubes at the following times: pre-dose (0 h),
0.5, 1 h (end of infusion), 1.25, 1.5, 2, 3, 4, 6, 8, 12, 16,
24, 36, 48, 60, 72 and 96 h after the start of the mica-
fungin infusion.
Plasma samples were prepared by protein precipitation
using acetonitrile. Samples were centrifuged within
30 min of collection at 3,000 rpm for 10 min at *4 C.
For each sample, four aliquots of 0.5 mL of the resulting
plasma fraction were prepared for PK analyses. The
plasma concentrations of micafungin and its metabolites
were determined using high-performance liquid chroma-
tography with fluorescence detection following validated
procedures (Groll et al. 2001; Yamato et al. 2002). The
lower limit of quantification (LLOQ) of plasma micafun-
gin and its metabolites M-1, M-2 and M-5 was 0.05 lg/
mL.
In addition, two aliquots of plasma (1 mL each), from
the blood samples collected 8 and 24 h after the start of
infusion, were used for determination of micafungin
plasma protein binding using an ultracentrifugation
method. Protein-bound and unbound micafungin were
separated using an ultrafiltration system (Centrifree MPS-
3, Millipore, Merck KGaA, Darmstadt, Germany). Plasma
samples were added to the filter reservoir of a micro-par-
tition ultrafiltration device and centrifuged at 3,000 rpm for
15 min at 37 C. The resulting ultrafiltrate was analysed
for unbound micafungin levels. The ratio of unbound mi-
cafungin to total micafungin in plasma was calculated as
ultrafiltrate concentration/plasma concentration.
2.5 PK analysis
The PK parameters determined for micafungin and its
metabolites were Cmax, AUC0–24, AUC from time 0 to the
last quantifiable concentration (AUClast), AUC?, t, CL
(micafungin only), volume of distribution (Vz; micafungin
only) and volume of distribution at steady state (Vss; mi-
cafungin only).
The Cmax was obtained directly from plasma micafungin
concentration–time data. AUC0–24 and AUClast were cal-
culated from the time of dosing to either the end of the
dosing period or to the last measurable concentration of
micafungin, respectively, by numeric integration using the
linear trapezoidal rule for ascending concentrations and the






Ci þ Ciþ1ð Þ; ð1Þ
where n is the number of data points, 0 ¼
t0\t1\   \tn\t are sampling times, and Ci is plasma
micafungin concentration from the sample at ti. AUC? was
estimated using
AUC1 ¼ AUCð0tÞ þ Ct
Ke
; ð2Þ
where Ct is the last measurable plasma concentration of
micafungin and Ke is the apparent terminal rate elimination
constant obtained by log-linear regression of the terminal








where F is the fraction of dose absorbed (which is
presumed to be 1 as it was an IV infusion) and D is the




where C0 is the extrapolated plasma micafungin
concentration at time 0. Lastly, Vss was calculated as
Vss ¼ DðAUMC1ÞðAUC1Þ2
; ð6Þ
where AUMC is the area under the first-moment curve.
2.6 Safety assessments
Subjects were monitored for adverse events (AEs)
throughout the study. Additional safety evaluations com-
prised vital signs assessment, physical examination,
12-lead electrocardiograms, urinalysis and urine micros-
copy and clinical laboratory measurements.
2.7 Statistical analysis
The PK analysis set included all subjects with evaluable
PK data who completed the study. The safety analysis set
included all subjects who received micafungin treatment.
Descriptive statistics were used to analyse subject demo-
graphics, laboratory measurements, vital signs and PK
data. Log-transformed values of Cmax, AUC0–24, AUClast,
AUC?, t and CL were analysed using an analysis of
variance model with group as main effect using PROC
MIXED of SAS (Version 8.2; SAS Institute Inc., Cary,
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NC, USA). The mean ratios and 90 % confidence intervals
(CIs) for the mean differences on the logarithmic scale
were transformed to obtain point estimates and 90 % CIs
for the respective mean ratios. 90 % CIs in the acceptance
range of 80–125 % were used to determine whether severe
hepatic dysfunction altered the extent of micafungin
exposure.
For subjects with severe hepatic dysfunction, multivar-
iate linear regression analysis with stepwise selection was
used to investigate the relationship between Cmax, AUC?
and CL for each plasma analyte (micafungin, M-1, M-2
and M-5) and hepatic function explanatory parameters (i.e.
Child–Pugh score, plasma albumin, total bilirubin, pro-
thrombin time and international normalised ratio).
All analyses, including calculation of PK parameters,
were conducted by a central laboratory (FARMOVS-
PAREXEL, Bloemfontein, South Africa) using WinNon-
lin Professional (Version 5.0.1, Pharsight Corporation,
Mountain View, CA, USA).
3 Results
3.1 Subjects
Eight subjects with severe hepatic dysfunction and eleven
subjects with normal hepatic function were included in this
study. These 19 subjects comprised the safety analysis set.
However, three of the subjects with normal hepatic func-
tion were excluded from the PK analysis due to protocol
violations (involving processing of plasma aliquots from
blood samples). Thus, the PK analysis set comprised the
eight subjects with severe hepatic dysfunction and eight
with normal hepatic function. Demographic characteristics
of the study participants are shown in Table 1. Subjects
were well matched for age, sex and body weight.
3.2 PK analysis
Mean plasma concentration versus time curves of mica-
fungin in subjects with severe hepatic dysfunction and
those with normal hepatic function are shown in Fig. 1. At
each time point, the mean plasma micafungin concentra-
tion was lower in subjects with severe hepatic dysfunction
compared with normal healthy subjects.
A summary of the micafungin PK parameters obtained
in subjects with severe hepatic dysfunction and healthy
subjects is shown in Table 2. Mean Cmax, AUC0–24,
AUClast and AUC? were lower in subjects with severe
hepatic dysfunction compared with healthy subjects. The
mean ratios for Cmax and AUC? were 69.2 % (90 % CI
51.3–93.5) and 68.2 % (90 % CI 50.8–91.5), respectively.
However, mean CL, Vz and Vss were higher in subjects with
severe hepatic dysfunction compared with healthy subjects
(mean ratio for CL was 146.7 % [90 % CI 109.3–196.8]),
while mean t was similar in both groups.
Mean plasma concentration versus time curves of the
metabolites M-1 and M-5 are shown in Fig. 2. Plasma
concentrations of M-2 were below LLOQ (0.05 lg/mL) at
all time points; therefore, no PK parameters were derived
for this metabolite. Plasma concentrations of M-1 metab-
olite were below LLOQ in all subjects with severe hepatic
dysfunction at all time points B12 h post-dosing and in all
but one subject with severe hepatic dysfunction at the 16-h
post-dose time point. Plasma concentrations of the M-1
metabolite were also below LLOQ in all subjects with
normal hepatic function at all time points up to 16 h post-
dosing. From 24 h post-dosing, mean M-1 plasma con-
centrations were similar in both groups.
For all subjects with severe hepatic dysfunction, plasma
concentrations of M-5 metabolite were measurable from
1–75 h post-dosing, but below LLOQ for three of these
subjects at the 96-h post-dose time point. For all healthy
subjects, plasma concentrations of M-5 metabolite were
measurable from 1.5–60 h post-dosing and below LLOQ at
the 96-h post-dose time point. At all time points, mean M-5
metabolite plasma concentrations were higher in subjects
with severe hepatic dysfunction compared with healthy
subjects.
A summary of the PK parameters of the M-1 metabolite
in subjects with severe hepatic dysfunction and in healthy
subjects is shown in Table 3. Mean AUC? and t were
lower in subjects with severe hepatic dysfunction com-
pared with healthy subjects. Point estimates for the ratios
of AUC? and t between the two groups were 79.5 %
(90 % CI 44.9–140.8) and 70.0 % (90 % CI 29.4–166.5),
respectively. Mean Cmax was similar in both groups.
PK parameters for the M-5 metabolite in subjects with
severe hepatic dysfunction and in subjects with normal







Number of subjects (n) 8 8
Male, n (%) 5 (62.5) 5 (62.5)
Age, mean (SD), years 54.5 (8.6) 50.1 (6.3)
Weight, mean (SD) (kg) 73.2 (20.2) 70.2 (15.5)
Race, n (%)
White 2 (25.0) 2 (25.0)
Coloureda 4 (50.0) 0
Mixed race 2 (25.0) 6 (75.0)
SD standard deviation
a Ethnic group as defined in a South African context
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hepatic function are summarised in Table 3. Mean Cmax,
AUC0–24, AUClast and AUC? were higher in subjects with
severe hepatic dysfunction compared with healthy subjects.
Point estimates for the ratios of Cmax and AUC? were
227.5 % (90 % CI 155.2–333.5) and 231.8 % (90 % CI
152.3–352.7), respectively. However, the t of M-5 was
similar in both subject groups.
To examine a potential cause for the different PK pro-
files between the study groups, free plasma protein con-
centrations were evaluated in eight subjects with severe
hepatic dysfunction and 11 healthy subjects. Mean serum
albumin concentrations were lower in subjects with severe
hepatic dysfunction [24.3 ± 7.1 g/L (Day 1), 22.6 ± 6.9 g/L
(Day 2) and 24.3 ± 8.6 g/L (Day 5)] compared with healthy
subjects [39.4 ± 2.1 g/L (Day-1), 36.5 ± 3.2 g/L (Day 2)
and 38.5 ± 3.1 g/L (Day 5)].
Plasma protein binding of micafungin was assessed in
all subjects but was only measurable in five subjects with
severe hepatic dysfunction and three healthy subjects. The
ratios of unbound plasma micafungin concentration
(ultrafiltrate) to total plasma micafungin concentration
ranged from 0.024 to 0.139 (86.1–97.6 % protein binding)
in subjects with severe hepatic dysfunction and from 0.010
to 0.076 (92.4–99.0 % protein binding) in healthy subjects.
Ultrafiltrate micafungin concentrations were below LLOQ
in the remaining subjects.
Linear regression analyses, conducted to examine the
relationships between PK parameters and hepatic
Fig. 1 Plasma micafungin
concentration versus time
profiles (geometric mean ± SD)
for subjects with severe hepatic
dysfunction (n = 8) and normal
hepatic function (n = 8)
Table 2 PK parameters of micafungin [geometric mean (SD)] in subjects with severe hepatic dysfunction and normal hepatic function
Parameter Subjects with severe
hepatic dysfunction (n = 8)
Subjects with normal
hepatic function (n = 8)
ANOVA results
Mean ratio (%)a (90 % CI) Coefficient of variation (%)
Cmax (lg/mL) 7.3 (2.4) 10.3 (2.5) 69.2 (51.3–93.5) 28.5
AUC0–24 (hlg/mL) 71.6 (24.5) 96.8 (20.7) 72.0 (53.6–96.5) 27.9
AUClast (hlg/mL) 98.2 (34.3) 140.6 (29.0) 67.7 (50.4–91.1) 28.2
AUC? (hlg/mL) 100.1 (34.5) 142.4 (28.9) 68.2 (50.8–91.5) 27.9
t (h) 13.7 (2.1) 14.9 (1.5) 91.2 (79.5–104.5) 12.8
CL (mL/h) 1,098 (347) 728 (149) 146.7 (109.3–196.8) 27.9
Vz (mL) 21,283 (5847) 15,742 (3979) NC NC
VSS (L) 19,903 (5670) 14,693 (3351) NC NC
ANOVA analysis of variance, NC not calculated
a Log-transformed mean value in subjects with severe hepatic dysfunction; log-transformed mean value in subjects with normal hepatic function
Eur J Drug Metab Pharmacokinet (2015) 40:285–293 289
measurements, revealed a trend toward a positive linear
relationship between the CL of micafungin and Child–
Pugh score (P = 0.0568), and positive linear relationships
between both Cmax and AUC? of M-5 metabolite and total
bilirubin (P\ 0.05 in each).
3.3 Safety assessments
Safety was evaluated in eight subjects with severe hepatic
dysfunction and eleven healthy subjects. Six AEs were
reported by four subjects: one subject with severe hepatic
dysfunction experienced dizziness and pruritus, and
another experienced nausea and vomiting; while one
healthy subject experienced headache and another experi-
enced pruritus. None of these AEs was considered to be
serious or to be related to micafungin, and none led to
discontinuation of the study. No clinically significant
changes in laboratory measures were reported at the end of
study, including alanine aminotransferase, aspartate ami-
notransferase, or bilirubin levels and prothrombin time.
4 Discussion
In this study, micafungin plasma concentrations and most
PK parameters were lower in subjects with severe hepatic
dysfunction, except for CL, which was higher in these
subjects; however, the magnitude of the differences was
not considered to be clinically meaningful. These findings
are consistent with a previous study of micafungin, in
which subjects with moderate hepatic dysfunction dis-
played lower Cmax and AUC values, but higher CL, com-
pared with healthy subjects (Hebert et al. 2005b). Likewise,
in a study of anidulafungin, there was a 33 % lower
exposure in subjects with severe hepatic dysfunction
compared with healthy controls (Dowell et al. 2007).
The recommended dose for the treatment of adults with
invasive candidiasis and candidaemia in adults is 100 mg
daily resulting in the mean steady-state AUC0–24 of
97 hlg/mL (Undre et al. 2012b). In the present study, a
dose of 100 mg yielded a mean AUC? of 100.1 hlg/mL
in subjects with severe hepatic dysfunction. These findings
Fig. 2 Plasma concentration versus time profiles (arithmetic mean ± SD) for the micafungin metabolites, M-1 (a, b) and M-5 (c, d), in subjects
with severe hepatic dysfunction (n = 8) and normal hepatic function (n = 8)
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suggest that dose adjustment is not required in subjects
with severe hepatic dysfunction.
Plasma concentrations of the M-1 metabolite were
negligible in the first 24 h, suggesting a very slow rate of
formation of this metabolite. For later time points, the
plasma concentration profile of the M-1 metabolite was
similar between the two study groups. Mean plasma con-
centrations of the M-5 metabolite, and its mean Cmax and
AUC values, were higher and more variable in subjects
with severe hepatic dysfunction compared with healthy
subjects. This suggests that patients with severe hepatic
impairment exhibit either a higher rate of formation or
lower CL of M-5 compared with healthy subjects; how-
ever, it is unknown which mechanism is responsible for
this observation. The PK of the M-1 and M-5 metabolites
has not been examined in subjects with moderate hepatic
dysfunction in previous studies.
As micafungin is metabolised in the liver prior to its
elimination, exposure would be expected to be higher in
subjects with severe hepatic dysfunction due to disrupted
micafungin metabolism. However, the PK profiles obtained
for micafungin and its metabolites suggest the opposite as
micafungin exposure was higher in healthy subjects with
normal hepatic function than in subjects with severe
hepatic dysfunction.
Micafungin is highly protein bound in plasma ([99 %)
(Astellas Pharma; Hebert et al. 2005b), primarily to albu-
min. Plasma albumin concentrations are often altered in the
presence of severe hepatic dysfunction, raising the possi-
bility that altered plasma albumin concentrations may have
impacted micafungin PK in subjects with severe hepatic
dysfunction (Hebert et al. 2005b). Consistent with this
hypothesis, subjects with severe hepatic dysfunction in this
study had lower concentrations of plasma albumin than
subjects with normal hepatic function. This resulted in an
increase in free drug levels in the subjects with severe
hepatic dysfunction which, in turn, led to increased CL in
these individuals. This may also explain why mean mica-
fungin Cmax and AUC values were lower in subjects with
hepatic dysfunction, but t remained unchanged.
Micafungin is one of three available echinocandin
antifungal agents. Existing evidence suggests that higher
exposure to caspofungin is associated with moderate
hepatic dysfunction and that this can be adjusted for using
dose reduction (Merck Sharp & Dohme Limited 2011;
Mistry et al. 2007; van der Elst et al. 2012). Anidulafungin
is not metabolised by the liver, and, therefore, dose
adjustments are not required in subjects with mild, mod-
erate or severe hepatic dysfunction (Pfizer Inc 2010).
Although systemic exposure to micafungin was lower in
subjects with severe hepatic dysfunction in this study, the
magnitude of this difference was not considered clinically
meaningful. Micafungin has demonstrated efficacy in
adults with invasive candidiasis and candidaemia, and in
adults with HIV and oesophageal candidiasis, at levels of
exposure similar to those attained in the present study
(Undre et al. 2012a, b). Furthermore, a comparison of the
free concentration of micafungin in the two popula-
tions showed that the fraction unbound is similar in the
two populations. Thus, despite lower total micafungin
Table 3 PK parameters of micafungin metabolites, M-1 and M-5 [geometric mean (SD)], in subjects with severe hepatic dysfunction and
normal hepatic function
Parameter Subjects with severe hepatic
dysfunction (n = 8)a
Subjects with normal hepatic
function (n = 8)a
ANOVA results
Mean ratio (%)b (90 % CIs) Coefficient of variation (%)
Metabolite M-1
Cmax (lg/mL) 0.1 (0.0) 0.1 (0.0) 102.2 (77.2–135.1) 26.5
AUC0–24 (hlg/
mL)
0.2 (0.3) 0.1 (0.1) 133.5 (69.2–257.3) 43.2
AUClast (hlg/mL) 3.9 (2.6) 3.5 (1.6) 88.0 (38.7–199.7) 89.2
AUC? (hlg/mL) 13.1 (5.1) 17.5 (11.9) 79.5 (44.9–140.8) 48.0
t (h) 98.5 (69.6) 154.0 (147.3) 70.0 (29.4–166.5) 78.2
Metabolite M-5
Cmax (lg/mL) 0.6 (0.4) 0.2 (0.0) 227.5 (155.2–333.5) 36.8
AUC0–24 (hlg/
mL)
11.5 (6.4) 4.9 (0.9) 218.1 (153.3–310.2) 33.8
AUClast (hlg/mL) 31.0 (20.9) 10.8 (1.7) 251.2 (164.5–383.6) 41.1
AUC? (hlg/mL) 34.1 (23.4) 12.9 (1.8) 231.8 (152.3–352.7) 40.7
t (h) 21.1 (2.7) 21.6 (4.9) 99.1 (82.0–119.7) 17.8
a n = 8 for all parameters except for AUC? and t1/2 in subjects with severe hepatic dysfunction (n = 5), and for the ANOVA calculation of
mean ratio of AUC0–24 (n = 4)
b Log-transformed mean value in subjects with severe hepatic dysfunction; log-transformed mean value in subjects with normal hepatic function
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exposure, the free concentrations considered to be phar-
macologically active were similar, suggesting that dose
adjustments are not required in subjects with severe hepatic
dysfunction. In addition, a single dose of micafungin
100 mg was well tolerated in subjects with severe hepatic
dysfunction and subjects with normal hepatic function, and
there were no safety concerns throughout the study.
5 Conclusion
In summary, the findings of the present study indicate that
although severe hepatic dysfunction affects micafungin
PK, the magnitude of changes is not considered clinically
meaningful and thus does not warrant dose adjustment in
these individuals. This study also provides additional
evidence showing that micafungin is well tolerated in
subjects with hepatic dysfunction after a single dose of
100 mg.
Acknowledgments This study was sponsored by Astellas. Medical
writing and editorial support was provided by Neil M. Thomas, PhD,
of Envision Scientific Solutions, funded by Astellas.
Conflict of interest Nasrullah Undre is an employee of Astellas
Pharma Europe Ltd., Chertsey, UK. Paul Stevenson was formerly an
employee of Astellas Pharma GmbH Munich, Germany. Benjamin
Pretorius was formerly an employee of Parexel International, South
Africa.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
Astellas Pharma (2013) Mycamine: summary of product characteris-
tics. http://www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Product_Information/human/000734/WC500031075.
pdf. Accessed 19 March 2012
Benjamin DK Jr, Smith PB, Arrieta A, Castro L, Sa´nchez PJ,
Kaufman D, Arnold LJ, Kovanda LL, Sawamoto T, Buell DN,
Hope WW, Walsh TJ (2010) Safety and pharmacokinetics of
repeat-dose micafungin in young infants. Clin Pharmacol Ther
87(1):93–99. doi:10.1038/clpt.2009.200
de Wet NT, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E,
Llanos EA, Fisco C, Lau W, Buell D (2005) A randomized,
double blind, comparative trial of micafungin (FK463) vs.
fluconazole for the treatment of oesophageal candidiasis.
Aliment Pharmacol Ther 21(7):899–907. doi:10.1111/j.1365-
2036.2005.02427.x
Dowell JA, Stogniew M, Krause D, Damle B (2007) Anidulafungin
does not require dosage adjustment in subjects with varying
degrees of hepatic or renal impairment. J Clin Pharmacol
47(4):461–470. doi:10.1177/0091270006297227
Fromtling RA (2002) Micafungin sodium (FK-463). Drugs Today
(Barc) 38(4):245–257
Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH,
Piscitelli SC, Bekersky I, Walsh TJ (2001) Compartmental
pharmacokinetics and tissue distribution of the antifungal
echinocandin lipopeptide micafungin (FK463) in rabbits. Anti-
microb Agents Chemother 45(12):3322–3327. doi:10.1128/
AAC.45.12.3322-3327.2001
Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns
J, Bekersky I (2005a) Concomitant tacrolimus and micafungin
pharmacokinetics in healthy volunteers. J Clin Pharmacol
45(9):1018–1024. doi:10.1177/0091270005279274
Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend
RW, Buell D, Keirns J, Bekersky I (2005b) Pharmacokinetics of
micafungin in healthy volunteers, volunteers with moderate liver
disease, and volunteers with renal dysfunction. J Clin Pharmacol
45(10):1145–1152. doi:10.1177/0091270005279580
Hebert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D,
Keirns J, Bekersky I (2005c) Concomitant cyclosporine and
micafungin pharmacokinetics in healthy volunteers. J Clin
Pharmacol 45(8):954–960. doi:10.1177/0091270005278601
Jarvis B, Figgitt DP, Scott LJ (2004) Micafungin. Drugs 64(9):
969–982
Keirns J, Sawamoto T, Holum M, Buell D, Wisemandle W, Alak A
(2007) Steady-state pharmacokinetics of micafungin and voric-
onazole after separate and concomitant dosing in healthy adults.
Antimicrob Agents Chemother 51(2):787–790. doi:10.1128/
AAC.00673-06
Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C,
Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V,
Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J,
Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O,
Koblinger S, Diekmann-Berndt H, Cornely OA (2007) Micafungin
versus liposomal amphotericin B for candidaemia and invasive
candidosis: a phase III randomised double-blind trial. Lancet
369(9572):1519–1527. doi:10.1016/S0140-6736(07)60605-9
Lass-Flo¨rl C (2009) The changing face of epidemiology of invasive
fungal disease in Europe. Mycoses 52(3):197–205
Merck Sharp & Dohme Limited (2011) Cancidas (caspofungin)
summary of product characteristics. Merck Sharp & Dohme
Limited. http://www.medicines.org.uk/emc/medicine/12843#
PHARMACOKINETIC_PROPS. Accessed 19 March 2012
Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller
MA (2006) Activities of micafungin against 315 invasive
clinical isolates of fluconazole-resistant Candida spp. J Clin
Microbiol 44(2):324–326. doi:10.1128/JCM.44.2.324-326.2006
Mistry GC, Migoya E, Deutsch PJ, Winchell G, Hesney M, Li S, Bi S,
Dilzer S, Lasseter KC, Stone JA (2007) Single- and multiple-
dose administration of caspofungin in patients with hepatic
insufficiency: implications for safety and dosing recommenda-
tions. J Clin Pharmacol 47(8):951–961. doi:10.1177/009127000
7303764
Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ,
Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli
AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell
DN (2007) Micafungin versus caspofungin for treatment of
candidemia and other forms of invasive candidiasis. Clin Infect
Dis 45(7):883–893. doi:10.1086/520980
Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidi-
asis: a persistent public health problem. Clin Microbiol Rev
20(1):133–163. doi:10.1128/CMR.00029-06
Pfizer Inc. (2010) EraxisTM (anidulafungin) prescribing information.
Pfizer Inc., http://labeling.pfizer.com/ShowLabeling.aspx?id=
566. Accessed 19 March 2012
Undre N, Stevenson P, Baraldi E (2012a) Pharmacokinetics of
micafungin in HIV positive patients with confirmed esophageal
candidiasis. Eur J Drug Metab Pharmacokinet 37(1):31–38.
doi:10.1007/s13318-011-0063-8
292 Eur J Drug Metab Pharmacokinet (2015) 40:285–293
Undre N, Stevenson P, Kuse ER, demeyer I (2012b) Pharmacokinet-
ics of micafungin in adult patients with invasive candidiasis and
candidemia. Open J Med Microbiol 2(3):84–90. doi:10.4236/
ojmm.2012.23012
Undre NA, Stevenson P, Freire A, Arrieta A (2012c) Pharmacoki-
netics of micafungin in pediatric patients with invasive candi-
diasis and candidemia. Pediatr Infect Dis J 31(6):630–632.
doi:10.1097/INF.0b013e31824ab9b0
van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH,
Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM,
Walsh TJ (2004) Micafungin versus fluconazole for prophylaxis
against invasive fungal infections during neutropenia in patients
undergoing hematopoietic stem cell transplantation. Clin Infect
Dis 39(10):1407–1416. doi:10.1086/422312
van der Elst KC, Bru¨ggemann RJ, Rodgers MG, Alffenaar JW (2012)
Plasma concentrations of caspofungin at two different dosage
regimens in a patient with hepatic dysfunction. Transpl Infect
Dis 14(4):440–443. doi:10.1111/j.1399-3062.2011.00716.x
Wiederhold NP, Lewis JS 2nd (2007) The echinocandin micafungin:
a review of the pharmacology, spectrum of activity, clinical
efficacy and safety. Expert Opin Pharmacother 8(8):1155–1166.
doi:10.1517/14656566.8.8.1155
Yamato Y, Kaneko H, Tanimoto K, Katashima M, Ishibashi K,
Kawamura A, Terakawa M, Kagayama A (2002) Simultaneous
determination of antifungal drug, micafungin, and its two active
metabolites in human plasma using high-performance liquid
chromatography with fluorescence detection. Jpn J Chemother
50:68–73
Eur J Drug Metab Pharmacokinet (2015) 40:285–293 293
